ArticleBlood cancer journal2025

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.

Minoru Kanaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.